<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83769">
  <stage>Registered</stage>
  <submitdate>30/03/2009</submitdate>
  <approvaldate>15/05/2009</approvaldate>
  <actrnumber>ACTRN12609000283279</actrnumber>
  <trial_identification>
    <studytitle>1. ASPECT - ASIA PACIFIC EVALUATION OF CHEST PAIN TRIAL An observational study of the diagnostic utility of a biomarker panel in the assessment of patients presenting to asia-paciifc hospitals with chest pain of possible cardiac origin</studytitle>
    <scientifictitle>1. ASPECT - ASIA PACIFIC EVALUATION OF CHEST PAIN TRIAL An observational study of the diagnostic utility of a biomarker panel in the assessment of patients presenting to asia-paciifc hospitals with chest pain of possible cardiac origin</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ASPECT</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>chest pain of possible cardiac origin</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>ASPECT: The Triage multi-marker panel consists of measurements of Troponin I, Creatine Kinase MB (CKMB) and myoglobin levels using a point of care testing device for blood samples taken from people who present with probable ischaemic chest pain to the Emergency Department. A sample is tested on arrival and again 2 hours later.</interventions>
    <comparator>n/a</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>ASPECT:To prospectively validate an accelerated chest pain algorithm involving Troponin I, Creatine Kinase MB (CKMB) and Myoglobin Delta measurements over a 2 hour time period from presentation to the Emergency Department (ED) in patients with possible Acute Coronary Syndrome (ACS) using the Biosite Triage point of care multi-marker panel</outcome>
      <timepoint>At presention to ethe emergency departmetn at Christchurch Hospital and again 2 hours later</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the potential cost benefit of such a strategy in terms of case weight costing and bed days.</outcome>
      <timepoint>From presenation to the Emergency Department at trial hospital , then at 30 days and 1 year for all cause readmission(s) and/or death.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Adults presenting to the trial hospital Emergency Department with chest pain of possible cardiac origin</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Age &lt; 18 years. Non-resident in country of recruitment. Patients for whom follow-up will not be possible either due to lack of onward contact address or because they will be overseas. Unable or unwilling to consent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>6/11/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>4000</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate />
    <postcode>4029</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Delhi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Beijing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Indonesia</country>
      <state>Jakarta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan, Province Of China</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Democratic People's Republic Of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Inverness Medical Innovations</primarysponsorname>
    <primarysponsoraddress>532 Seventeen Miles Rocks Rd
Sinnamon Park, QLD 4073</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Inverness Medical Innovations</fundingname>
      <fundingaddress>532 Seventeen Miles Rocks Rd
Sinnamon Park, QLD 4073</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Research Council New Zealand</fundingname>
      <fundingaddress>PO Box 5541, Wellesley Street, Auckland 1141</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research (Australia)</fundingname>
      <fundingaddress>National Health and Medical Research Council
 GPO Box 1421
 Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Christchurch Cardio-Endocrine Research Group</fundingname>
      <fundingaddress>Department of Medicine
Christchurch Hospital
New Zealand</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Charities/Societies/Foundations</sponsortype>
      <sponsorname>Emergency Care Foundation</sponsorname>
      <sponsoraddress>Emergency Department 
Christchurch Hospital
PO Box 4710
Christchurch</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a prospective observational study of the diagnostic utility of the "Triage" multi-marker point of care blood testing device to measure the levels of the cardiac markers Troponin I, Creatine Kinase MB and myoglobin:
- in people presenting to the Emergency Deprtment with chest pain of probable caridac origin. Blood samples will be taken and tested on arrival and again at 2 hours. Participants will undergo risk evaluation by a means of a set series of questions. Participants will recieve a phone call at 45 days, 6 months and 1 year post discharge to record any major adverse cardiac event (MACE) they may have experienced.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Upper South A Regional Ethics Committee</ethicname>
      <ethicaddress>Ministry of health
PO Box 3877
Christchurch</ethicaddress>
      <ethicapprovaldate>26/07/2007</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Martin Than</name>
      <address>Emergency Department 
Christchurch Hospital
PO Box 4710
Christchurch</address>
      <phone>+643 364 0270</phone>
      <fax>+643 364 0286</fax>
      <email>martin.than@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Martin Than</name>
      <address>Emergency Department 
Christchurch Hospital
PO Box 4710
Christchurch</address>
      <phone>+643 364 0270</phone>
      <fax>+643 364 0286</fax>
      <email>martin.than@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Lorraine Skelton</name>
      <address>Department of Medicine
University of Otago, Christchurch
PO Box 4345
Christchurch</address>
      <phone>+643 364 1063</phone>
      <fax>+643 364 1115</fax>
      <email>lorraine.skelton@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>